Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus
出版年份 2023 全文链接
标题
Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus
作者
关键词
-
出版物
Frontiers in Endocrinology
Volume 14, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2023-02-13
DOI
10.3389/fendo.2023.1125693
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Roles of Mineralocorticoid Receptors in Cardiovascular and Cardiorenal Diseases
- (2022) Jonatan Barrera-Chimal et al. Annual Review of Physiology
- The Role of Aldosterone in OSA and OSA-Related Hypertension
- (2022) Yi Wang et al. Frontiers in Endocrinology
- Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE)
- (2022) Jennifer B Green et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- The Extraglycemic Effect of SGLT-2is on Mineral and Bone Metabolism and Bone Fracture
- (2022) Bingzi Dong et al. Frontiers in Endocrinology
- Cardiovascular and Renal Outcomes with Finerenone, a Selective Mineralocorticoid Receptor Antagonist
- (2022) Srikanth Palanisamy et al. Cardiology and Therapy
- Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2022) Melanie J. Davies et al. DIABETOLOGIA
- Efficacy and safety of finerenone in chronic kidney disease associated with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials
- (2022) Wujisiguleng Bao et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Mineralocorticoid Receptor Antagonism by Finerenone Attenuates Established Pulmonary Hypertension in Rats
- (2022) Ly Tu et al. HYPERTENSION
- Analysis from the FIDELITY study examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes.
- (2022) George L. Bakris et al. KIDNEY INTERNATIONAL
- SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials
- (2022) Muthiah Vaduganathan et al. LANCET
- Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease
- (2022) Gerasimos Filippatos et al. European Heart Journal-Cardiovascular Pharmacotherapy
- Effect of finerenone on the occurrence of vision‐threatening complications in patients with non‐proliferative diabetic retinopathy: Pooled analysis of two studies using routine ophthalmological examinations from clinical trial participants ( ReFineDR / DeFineDR )
- (2022) Peter Rossing et al. DIABETES OBESITY & METABOLISM
- Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study
- (2021) George Bakris et al. HYPERTENSION
- Finerenone Reduces Onset of Atrial Fibrillation in Patients with Chronic Kidney Disease and Type 2 Diabetes
- (2021) Gerasimos Filippatos et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage
- (2021) Peter Kolkhof et al. AMERICAN JOURNAL OF NEPHROLOGY
- Activation of Rac1-Mineralocorticoid Receptor Pathway Contributes to Renal Injury in Salt-Loaded db/db Mice
- (2021) Daigoro Hirohama et al. HYPERTENSION
- Semiquantitative assessed proteinuria and risk of heart failure: Analysis of a nationwide epidemiological database
- (2021) Akira Fukui et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
- (2021) Bertram Pitt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Mineralocorticoid Receptor Antagonism and ACE Inhibition on Angiotensin Profiles in Diabetic Kidney Disease: An Exploratory Study
- (2021) Johannes J. Kovarik et al. Diabetes Therapy
- Mineralocorticoid receptor in cardiovascular diseases—Clinical trials and mechanistic insights
- (2021) Johann Bauersachs et al. BRITISH JOURNAL OF PHARMACOLOGY
- Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial
- (2021) Gerasimos Filippatos et al. CIRCULATION
- Finerenone Dose–Exposure–Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria
- (2021) Sebastiaan Camiel Goulooze et al. CLINICAL PHARMACOKINETICS
- Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP‐1RA treatment: A subgroup analysis from the FIDELIO‐DKD trial
- (2021) Peter Rossing et al. DIABETES OBESITY & METABOLISM
- Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
- (2021) Rajiv Agarwal et al. EUROPEAN HEART JOURNAL
- Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics
- (2021) Jonatan Barrera-Chimal et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial
- (2021) Rajiv Agarwal et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders − New perspectives for combination therapy
- (2021) Peter Kolkhof et al. PHARMACOLOGICAL RESEARCH
- Diagnosis and treatment of primary aldosteronism
- (2021) Martin Reincke et al. Lancet Diabetes & Endocrinology
- Spironolactone use is associated with improved outcomes in heart failure with mid‐range ejection fraction
- (2020) Nobuyuki Enzan et al. ESC Heart Failure
- The novel non‐steroidal MR antagonist finerenone improves metabolic parameters in high‐fat diet‐fed mice and activates brown adipose tissue via AMPK‐ATGL pathway
- (2020) Vincenzo Marzolla et al. FASEB JOURNAL
- Aldosterone, Inflammation, Immune System, and Hypertension
- (2020) Nathanne S Ferreira et al. AMERICAN JOURNAL OF HYPERTENSION
- Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose–response study and open-label extension study
- (2020) Takashi Wada et al. Clinical and Experimental Nephrology
- Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
- (2020) Rajiv Agarwal et al. EUROPEAN HEART JOURNAL
- Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
- (2020) George L. Bakris et al. NEW ENGLAND JOURNAL OF MEDICINE
- The effect of aldosterone and aldosterone blockade on the progression of chronic kidney disease: a randomized placebo-controlled clinical trial
- (2020) Hitoshi Minakuchi et al. Scientific Reports
- A Prospective Single-Blind Randomized Trial of Ramipril, Eplerenone and Their Combination in Type 2 Diabetic Nephropathy
- (2020) Mostafa El Mokadem et al. CardioRenal Medicine
- Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN)
- (2020) Sadayoshi Ito et al. Clinical Journal of the American Society of Nephrology
- Mineralocorticoid Antagonism and Diabetic Kidney Disease
- (2019) Yuliya Lytvyn et al. Current Diabetes Reports
- Efficacy and safety of mineralocorticoid receptor antagonists with ACEI/ARB treatment for diabetic nephropathy: A meta‐analysis
- (2019) Chao Zuo et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2019) Søren L Kristensen et al. Lancet Diabetes & Endocrinology
- Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study)
- (2019) Sadayoshi Ito et al. HYPERTENSION
- Mineralocorticoid Receptor Blockers and Aldosterone to Renin Ratio: A Randomized Controlled Trial and Observational Data
- (2018) Stefan Pilz et al. HORMONE AND METABOLIC RESEARCH
- Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone’s Antifibrotic ActivityNovelty and Significance
- (2018) Jana Grune et al. HYPERTENSION
- Spironolactone Versus Clonidine as a Fourth-Drug Therapy for Resistant HypertensionNovelty and Significance
- (2018) Eduardo M. Krieger et al. HYPERTENSION
- The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling
- (2018) Jonatan Barrera-Chimal et al. KIDNEY INTERNATIONAL
- The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure
- (2018) Hui Pei et al. MEDICINE
- Long-Term Effects of Spironolactone on Kidney Function and Hyperkalemia-Associated Hospitalization in Patients with Chronic Kidney Disease
- (2018) Chen-Ta Yang et al. Journal of Clinical Medicine
- Canrenone on cardiovascular mortality in congestive heart failure
- (2018) Giuseppe Derosa et al. PHARMACOLOGICAL RESEARCH
- Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Protects Against Acute Kidney Injury–Mediated Chronic Kidney DiseaseNovelty and Significance
- (2017) Lionel Lattenist et al. HYPERTENSION
- Effect of spironolactone on the risks of mortality and hospitalization for heart failure in pre-dialysis advanced chronic kidney disease: A nationwide population-based study
- (2017) Wei-Cheng Tseng et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Antialbuminuric effect of eplerenone in comparison to thiazide diuretics in patients with hypertension
- (2017) Toshiki Sawai et al. Journal of Clinical Hypertension
- Low dose-eplerenone treatment decreases aortic stiffness in patients with resistant hypertension
- (2017) Tatjana Kalizki et al. Journal of Clinical Hypertension
- 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development
- (2017) Peter Kolkhof et al. JOURNAL OF ENDOCRINOLOGY
- Low-dose eplerenone decreases left ventricular mass in treatment-resistant hypertension
- (2017) Andreas Schneider et al. JOURNAL OF HYPERTENSION
- Global aetiology and epidemiology of type 2 diabetes mellitus and its complications
- (2017) Yan Zheng et al. Nature Reviews Endocrinology
- The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury
- (2017) Jochen Dutzmann et al. PLoS One
- Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes
- (2016) Nisa M. Maruthur et al. ANNALS OF INTERNAL MEDICINE
- A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
- (2016) Gerasimos Filippatos et al. EUROPEAN HEART JOURNAL
- Finerenone: third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease
- (2015) Licette CY Liu et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Comparison of eplerenone and spironolactone for the treatment of primary aldosteronism
- (2015) Shigehiro Karashima et al. HYPERTENSION RESEARCH
- Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy
- (2015) George L. Bakris et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1
- (2015) Larbi Amazit et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury
- (2014) Peter Kolkhof et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Spironolactone for Heart Failure with Preserved Ejection Fraction
- (2014) Bertram Pitt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
- (2013) Bertram Pitt et al. EUROPEAN HEART JOURNAL
- The cardioprotective effects of mineralocorticoid receptor antagonists
- (2013) T.N.A. van den Berg et al. PHARMACOLOGY & THERAPEUTICS
- Results of the Randomized Aldosterone Antagonism in Heart Failure With Preserved Ejection Fraction Trial (RAAM-PEF)
- (2011) Anita Deswal et al. JOURNAL OF CARDIAC FAILURE
- Aldosterone: effects on the kidney and cardiovascular system
- (2010) Marie Briet et al. Nature Reviews Nephrology
- Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms
- (2010) Faiez Zannad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results
- (2009) Alessandro Boccanelli et al. EUROPEAN JOURNAL OF HEART FAILURE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now